Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Anika Therapeutics (ANIK) over the last 3 years, with Q3 2021 value amounting to $400000.0.

  • Anika Therapeutics' Amortization of Deferred Charges fell 267.64% to $400000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.7 million, marking a year-over-year increase of 1895.47%. This contributed to the annual value of $1.5 million for FY2020, which is 2985.58% up from last year.
  • As of Q3 2021, Anika Therapeutics' Amortization of Deferred Charges stood at $400000.0, which was down 267.64% from $507000.0 recorded in Q2 2021.
  • In the past 5 years, Anika Therapeutics' Amortization of Deferred Charges registered a high of $507000.0 during Q2 2021, and its lowest value of $289000.0 during Q3 2019.
  • In the last 3 years, Anika Therapeutics' Amortization of Deferred Charges had a median value of $385000.0 in 2020 and averaged $365636.4.
  • In the last 5 years, Anika Therapeutics' Amortization of Deferred Charges skyrocketed by 4221.45% in 2020 and then plummeted by 267.64% in 2021.
  • Over the past 3 years, Anika Therapeutics' Amortization of Deferred Charges (Quarter) stood at $299000.0 in 2019, then skyrocketed by 32.11% to $395000.0 in 2020, then rose by 1.27% to $400000.0 in 2021.
  • Its Amortization of Deferred Charges was $400000.0 in Q3 2021, compared to $507000.0 in Q2 2021 and $405000.0 in Q1 2021.